Effect of mergers and acquisitions on drug discovery: perspective from a case study of a Japanese pharmaceutical company

Drug Discovery Today

Volumn 13, Issue 1-2, 2008, Pages 86-93

  Shibayama, Sotaro ^a,b   Tanikawa, Kunihiro ^a   Fujimoto, Ryuhei ^c   Kimura, Hiromichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DECISION MAKING; DRUG INDUSTRY; DRUG RESEARCH; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HEALTH SERVICE; JAPAN; MERGERS AND ACQUISITIONS; PHARMACEUTICAL CARE; REVIEW; SCIENTIST;

DRUG DESIGN; DRUG INDUSTRY; JAPAN; KNOWLEDGE BASES; NEGOTIATING; ORGANIZATIONAL INNOVATION; PRIVATE SECTOR; RESEARCH;

EID: 37649033180     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.10.015     Document Type: Review

References (41)

1. Pavlou A.K., and Belsey M.J. BioPharma licensing and M&A trends. Nat. Rev. Drug Discov. 4 (2005) 273-274
2. Danzon, P.M. et al. (2004) Mergers and acquisitions in the pharmaceutical and biotech industries. NBER Working Paper 10536 (http://www.nber.org/papers/w10536)
3. IBM Business Consulting Service (2003) Pharma 2010: The threshold of innovation
4. Frantz S. Pipeline problems are increasing the urge to merge. Nat. Rev. Drug Discov. 5 (2006) 977-979
5. Merck & Co. (2006) Merck & Co., Inc. to acquire Sirna Therapeutic Inc. Press Release Octtober 30 (http://www.merck.com/newsroom/press_releases/corporate/2006_1030.html)
6. Johnson & Johnson and ALZA Corporation (2001) Johnson & Johnson to merge with ALZA Corporation in $10.5 billion stock-for-stock transaction. Press Release March 27 (http://www.alza.com/alza/pr_03272001)
7. Hitt M.A., and Hoskisson R.E. Mergers and acquisitions and managerial commitment to innovation in M-form firms. Strateg. Manag. J. 11 (1990) 29-47
8. Miller R.R. Do mergers and acquisitions hurt R&D?. Res. Technol. Manag. 33 (1990) 11-15
9. Hitt M.A., et al. Effects of acquisitions on research-and-development inputs and outputs. Acad. Manage. J. 34 (1991) 693-706
10. Ernst H., and Vitt J. The influence of corporate acquisitions on the behaviour of key inventors. R&D Manag. 30 (2000) 105-119
11. Ahuja G., and Katila R. Technological acquisitions and the innovation performance of acquiring firms: a longitudinal study. Strateg. Manag. J. 22 (2001) 197-220
12. Cassiman B., et al. The impact of M&A on the R&D process: an empirical analysis of the role of technological- and market-relatedness. Res. Policy 34 (2005) 195-220
13. Cloodt M., et al. Mergers and acquisitions: their effect on the innovative performance of companies in high-tech industries. Res. Policy 35 (2006) 642-654
14. Hemmert M. The influence of institutional factors on the technology acquisition performance of high-tech firms: survey results from Germany and Japan. Res. Policy 33 (2004) 1019-1039
15. Prabhu J.C., et al. The Impact of acquisitions on innovation poison pill, placebo, or tonic. J. Mark. 69 (2005) 114-130
16. Ruckman K. Technology sourcing through acquisitions: evidence from the US drug industry. J. Int. Bus. Stud. 36 (2005) 89-103
17. Schweizer L. Organizational integration of acquired biotechnology companies into pharmaceutical companies: the need for a hybrid approach. Acad. Manage. J. 48 (2005) 1051-1074
18. Paruchuri S., et al. Acquisition integration and productivity losses in the technical core: disruption of inventors in acquired companies. Organ. Sci. 17 (2006) 545-562
19. Nahavandi A. Acculturation in mergers and acquisitions. Acad. Manag. J. 13 (1988) 79-90
20. Baker J. Pfizer to cut 2000 R&D jobs. Eur. Chem. News 78 (2003) 9
21. Bayer, A.G. (2007) Bayer HealthCare announces concrete plans for the global synergy goals and job cuts. Press Release March 2 (http://www.bayer.com/en/News-Detail.aspx?id=9547)
22. Engleman, E. (2006) 700 ICOS workers to get pink slips from Lilly. Bus. J. December 12 (http://www.bizjournals.com/seattle/stories/2006/12/11/daily15.html)
23. Fletcher L. Pfizer-Pharmacia merger bodes ill for biotech?. Nat. Biotechnol. 20 (2002) 855-858
24. Seo M.G., and Hill N.S. Understanding the human side of merger and acquisition: an integrative framework. J. Appl. Behav. Sci. 41 (2005) 422-443
25. Nonaka I. A dynamic theory of organizational knowledge creation. Organ. Sci. 5 (1994) 14-37
26. Jarvis L.M. Pharmaceutical diaspora. Chem. Eng. News 85 (2007) 29
27. Hoke F. Smaller biotechs capturing top talent from large pharmaceutical competitors: stock options and openness to independent personalities are increasing the appeal of smaller firms for creative, ambitious scientists. Scientist 9 (1995) 1
28. Amabile T.M., et al. Affect and creativity at work. Adm. Sci. Q. 50 (2005) 367-403
29. Solvay, S.A. (2005) Solvay signs agreement aiming at acquisition of Fournier Pharma. Press Release March 24 (http://www.solvaypress.com/pressreleases/0,27907-2-0,00.htm)
30. Merck KGaA (2006) Merck KGaA announces acquisition of Serono SA. Press Release September 21 (http://www.merck.de/servlet/PB/show/1526220/)
31. Hattori, N. eds (2004) Practical M&A Management, Toyo-Keizai
32. Sams-Dodd F. Research & market strategy: how choice of drug discovery approach can affect market position. Drug Discov. Today 12 (2007) 314-318
33. Bozeman B., and Corley E. Scientists' collaboration strategies: implications for scientific and technical human capital. Res. Policy 33 (2004) 599-616
34. Vinas T. Amgen's land of discovery. Ind. Week 253 (2004) 87
35. Amy B., et al. Addicted to mergers?. Bus. Week 3658 (1999) 84-88
36. Chiesa V., and Manzini R. Profiting from the virtual organization of technological innovation: suggestions from an empirical study. Int. J. Technol. Manage. 15 (1998) 109-123
37. Criscuolo P. On the road again: researcher mobility inside the R&D network. Res. Policy 34 (2005) 1350-1365
38. Astellas Pharma Inc. (2004) Joint meeting on Yamanouchi and Fujisawa merger
39. Astellas Pharma Inc. (2005) Astellas R&D meeting
40. Astellas Pharma Inc. (2006) Securities report
41. FactSet Mergerstat eds (1981-2007) Mergerstat Review, WT Grimm